Report Finds 89% of Total U.S. Patent Applications on Humira Were Filed After FDA Approval – Pointing to a Deliberate Strategy to Delay Competition
Submission to FTC on the Role of Intellectual Property
Major Win for Patients as Brazil Rejects a Key Patent on Gilead Hepatitis C Drug and European Court of Justice Opinion Denies Patent Extension to Gilead’s HIV Drug
Non-profit group continues battle against Gilead patents
Medicines access group takes aim at Sovaldi patents
As more countries around the world reject unmerited patents for Sovaldi®, I-MAK Files Two New U.S. Patent Challenges on Gilead’s Hepatitis C Portfolio
Argentina Rejects Key Patent on Hepatitis C Drug
Patent ‘Trolls’ Recede as Threat to Innovation. Will Justices Change That?
Seven Days
Nonprofit Group I-MAK Files IPR Petitions Seeking to Invalidate Hepatitis C Drug Patent
1
2